Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danuglipron Phase 1 in Japanese adults with T2DM
NCT04552470Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of danuglipron in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), Number of Participants With Clinical Laboratory Abnormalities and 2 more. Started Oct 2020; status: completed.
02
Drugs
danuglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04552470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04552470.